

Susan Groshen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2253121/publications.pdf>

Version: 2024-02-01

50
papers

2,854
citations

236925

25
h-index

206112

48
g-index

51
all docs

51
docs citations

51
times ranked

4578
citing authors

#	ARTICLE	IF	CITATIONS
1	A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. <i>Cell Metabolism</i> , 2015, 22, 86-99.	16.2	635
2	Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	363
3	p53 and treatment of bladder cancer. <i>Nature</i> , 1997, 385, 123-124.	27.8	266
4	Follicular lesions of thyroid. <i>Cancer</i> , 2000, 90, 335-341.	4.1	157
5	Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Tj ETQq1 1 0.784314 105 /Over	7.0	62
6	Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy. , 1997, 79, 1767-1775.		103
7	Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2679-2686.	7.0	69
8	Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. <i>Cancer</i> , 2001, 91, 90-100.	4.1	68
9	A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1349-1356.	1.5	66
10	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 2715-2721.	7.0	62
11	Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1250-1258.	2.5	59
12	Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 6142-6149.	7.0	55
13	Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 580-601.	1.0	55
14	Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 1-8.	2.3	40
15	Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6277-6283.	7.0	39
16	GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant <i>Kras</i> -driven pancreatic tumorigenesis in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4020-E4029.	7.1	39
17	Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables. <i>Journal of Surgical Oncology</i> , 2015, 112, 125-132.	1.7	38
18	Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. <i>Clinical Cancer Research</i> , 2017, 23, 5374-5383.	7.0	38

#	ARTICLE	IF	CITATIONS
19	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3514.	1.6	38
20	Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 901-911.	1.7	35
21	Expression and Functional Role of Orphan Receptor GPR158 in Prostate Cancer Growth and Progression. <i>PLoS ONE</i> , 2015, 10, e0117758.	2.5	34
22	Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2020, 17, 189.	7.2	34
23	Biliary-Enteric Drainage vs Primary Liver Transplant as Initial Treatment for Children With Biliary Atresia. <i>JAMA Surgery</i> , 2019, 154, 26.	4.3	32
24	Pilot study of intravenous melphalan combined with continuous infusion L-methionine sulfoximine for children with recurrent neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1739-1746.	1.5	31
25	Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease. <i>Journal of Hepatology</i> , 2017, 67, 517-525.	3.7	31
26	Effects of recipient size and allograft type on pediatric liver transplantation for biliary atresia. <i>Liver Transplantation</i> , 2017, 23, 221-233.	2.4	31
27	Contrast-Enhanced Ultrasound Imaging of Breast Masses: Adjunct Tool to Decrease the Number of False-Positive Biopsy Results. <i>Journal of Ultrasound in Medicine</i> , 2019, 38, 2259-2273.	1.7	27
28	Attitudes and barriers to the use of donation after cardiac death livers: Comparison of a United States transplant center survey to the united network for organ sharing data. <i>Liver Transplantation</i> , 2017, 23, 1372-1383.	2.4	25
29	Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1108-1115.	1.6	24
30	Association of high microvessel density and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. <i>Oncotarget</i> , 2017, 8, 52193-52210.	1.8	24
31	High frequency of simultaneous loss of p16 and p16 gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach. <i>Oncogene</i> , 1997, 15, 1481-1488.	5.9	23
32	Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. <i>Clinical Cancer Research</i> , 2017, 23, 4550-4555.	7.0	23
33	The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0RO Prostate Cancer? A Multi-Institutional Study. <i>Advances in Radiation Oncology</i> , 2019, 4, 96-102.	1.2	23
34	Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate. <i>Cancer</i> , 1995, 76, 1621-1628.	4.1	21
35	A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 742-749.	1.9	21
36	An alternative approach to the optimal design of an LD50 bioassay. <i>Statistics in Medicine</i> , 1995, 14, 841-852.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017, 77, 13-20.	2.8	19
38	<i>AXIN2</i> expression predicts prostate cancer recurrence and regulates invasion and tumor growth. <i>Prostate</i> , 2016, 76, 597-608.	2.3	14
39	Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery. <i>Journal of Neurosurgery</i> , 2016, 125, 31-39.	1.6	13
40	Thyroid Lesions Visualized on CT. <i>Academic Radiology</i> , 2015, 22, 203-209.	2.5	12
41	No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses. <i>Clinical Breast Cancer</i> , 2017, 17, 510-515.	2.4	10
42	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223. <i>Cancer Treatment and Research Communications</i> , 2019, 18, 100114.	1.7	9
43	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 301.e17-301.e28.	1.6	7
44	Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study. <i>Cancer Medicine</i> , 2021, 10, 3004-3012.	2.8	6
45	LEA.135 expression: An independent and favorable prognostic biomarker for patients with primary invasive breast cancer. <i>International Journal of Cancer</i> , 2000, 89, 224-229.	5.1	3
46	Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method. <i>Pharmaceutical Statistics</i> , 2019, 18, 659-670.	1.3	2
47	Follicular lesions of thyroid. <i>Cancer</i> , 2000, 90, 335-341.	4.1	2
48	Peripheral Blood Stem Cells Harvested During Marrow Recovery from Disease-Specific Chemotherapy Shorten Duration of Neutropenia in Patients Undergoing Autologous Bone Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 1993, 9, 485-493.	1.3	1
49	Active surveillance: Do low-income patients adhere to the protocol?. <i>Journal of Clinical Oncology</i> , 2017, 35, 53-53.	1.6	1
50	Modulation of radiation biomarkers in a randomized phase II study of 131I-MIBG with or without radiation sensitizers for resistant/relapsed neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22514-e22514.	1.6	0